Frequently Asked Questions (FAQs)

Tetanus is a toxin that is produced by a bacterium called Clostridium tetani. These bacteria cannot grow if exposed to oxygen, which is why very deep wounds can be prone to infection. The spores produced by the bacteria cause an acute, life-threatening disease and are extremely hard to kill because they are resistant to both heat and many chemical agents that are used to eliminate bacteria.1

The spores responsible for tetanus can be found in soil and in intestines and feces of many household and farm animals. The bacteria can enter the body through a puncture wound. Tetanus cannot be spread from person to person.

There are 3 types of tetanus, with generalized tetanus being the most common type. The symptoms of generalized tetanus most commonly seen are spasms in the jaw muscle, followed by stiffness of the neck, difficulty swallowing, and rigidity of the abdominal muscles. Other symptoms include fever, sweating, elevated blood pressure, and rapid heart rate. Spasms often occur and may last for several minutes and continue for 3 to 4 weeks. Complete recovery, if it occurs, may take months.

Tetanus can be fatal; the best treatment for tetanus is prevention. You should make sure that your patients are up-to-date with tetanus vaccinations. If your patient has a wound that could possibly be contaminated by tetanus, or you're unsure of their immunization status, they will need both a dose of tetanus immune globulin (TIG)—such as HyperTET S/D—as soon as possible and a tetanus-and-diphtheria-containing vaccine (Td or Tdap).

TIG is a treatment that contains high levels of tetanus antibodies. An immune globulin works much faster than a vaccine but does not last as long. Because of the potentially life-threatening nature of tetanus, give your patients a TIG shot, such as HyperTET S/D and vaccine to make sure they get the comprehensive care they need.1

HyperTET S/D should be administered following injury in patients whose tetanus immunization is incomplete or uncertain. Standard therapy for the treatment of active tetanus, including the use of Hyper TET S/D, must be implemented immediately. View dosage information in the full Prescribing Information to make sure you are administering the proper dosage for the severity of the infection.

HyperTET S/D provides rapid immune protection for up to 21 days. Peak blood levels of immunoglobulin G (IgG) are obtained approximately 2 days after intramuscular injection. The half-life of IgG in the circulation of individuals with normal IgG levels is approximately 23 days.2

HyperTET® S/D (tetanus immune globulin [human]) is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain.

HyperTET S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations.

In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HyperTET S/D should be given only if the expected benefits outweigh the risks.

Slight soreness at the site of injection and slight temperature elevation may be noted at times. Sensitization to repeated injections of human immunoglobulin is extremely rare. In the course of routine injections of large numbers of persons with immunoglobulin, there have been a few isolated occurrences of angioneurotic edema, nephrotic syndrome, and anaphylactic shock after injection. Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after tetanus immune globulin (human) administration.

HyperTET S/D is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

Please see full Prescribing Information for HyperTET S/D.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


References:

  1. Centers for Disease Control and Prevention. Tetanus. In: Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015:341-352. https:/www.cdc.gov/vaccines/pubs/pinkbook/downloads/tetanus.pdf. Accessed July 1, 2019.
  2. HyperTET S/D (tetanus immune globulin [human]) Prescribing Information. Grifols.